OneDigital Investment Advisors LLC Sells 2,842 Shares of Abbott Laboratories (NYSE:ABT)

OneDigital Investment Advisors LLC lessened its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 8.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 31,527 shares of the healthcare product maker's stock after selling 2,842 shares during the quarter. OneDigital Investment Advisors LLC's holdings in Abbott Laboratories were worth $3,566,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Morse Asset Management Inc purchased a new stake in Abbott Laboratories during the third quarter valued at about $380,000. Tudor Financial Inc. purchased a new position in shares of Abbott Laboratories during the 3rd quarter valued at about $302,000. Anchor Investment Management LLC lifted its position in Abbott Laboratories by 2.9% in the 3rd quarter. Anchor Investment Management LLC now owns 54,237 shares of the healthcare product maker's stock worth $6,184,000 after buying an additional 1,509 shares during the last quarter. Fulcrum Equity Management purchased a new stake in Abbott Laboratories in the third quarter worth approximately $239,000. Finally, Wilmington Savings Fund Society FSB raised its stake in shares of Abbott Laboratories by 32.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 332,189 shares of the healthcare product maker's stock worth $37,873,000 after acquiring an additional 81,669 shares in the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ABT has been the topic of several recent research reports. UBS Group increased their target price on shares of Abbott Laboratories from $146.00 to $148.00 and gave the company a "buy" rating in a report on Thursday, January 23rd. Morgan Stanley boosted their target price on Abbott Laboratories from $117.00 to $127.00 and gave the company an "equal weight" rating in a research note on Thursday, April 17th. StockNews.com lowered Abbott Laboratories from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, February 12th. Evercore ISI increased their price objective on Abbott Laboratories to $136.00 and gave the company a "buy" rating in a research note on Thursday, January 2nd. Finally, Argus upgraded shares of Abbott Laboratories to a "strong-buy" rating in a report on Tuesday, January 28th. Four research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $142.59.

Insider Activity at Abbott Laboratories

In other news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of Abbott Laboratories stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $128.50, for a total value of $3,054,573.50. Following the sale, the executive vice president now directly owns 125,697 shares of the company's stock, valued at approximately $16,152,064.50. The trade was a 15.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Andrea F. Wainer sold 949 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $138.17, for a total value of $131,123.33. Following the completion of the sale, the executive vice president now directly owns 74,381 shares in the company, valued at approximately $10,277,222.77. The trade was a 1.26 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 116,449 shares of company stock valued at $15,463,316. 0.46% of the stock is owned by company insiders.

Abbott Laboratories Stock Performance

Shares of ABT stock traded down $0.49 during mid-day trading on Friday, reaching $128.90. 4,849,055 shares of the company's stock traded hands, compared to its average volume of 6,063,204. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. The firm has a market capitalization of $223.55 billion, a PE ratio of 16.85, a price-to-earnings-growth ratio of 2.52 and a beta of 0.80. Abbott Laboratories has a 12 month low of $99.71 and a 12 month high of $141.23. The firm has a 50 day moving average price of $130.54 and a two-hundred day moving average price of $122.41.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 EPS for the quarter, topping analysts' consensus estimates of $1.07 by $0.02. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The business had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.38 billion. On average, research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be issued a $0.59 dividend. This represents a $2.36 annualized dividend and a yield of 1.83%. The ex-dividend date is Tuesday, April 15th. Abbott Laboratories's dividend payout ratio is currently 30.61%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.